newsfilter
← Latest News
Business Wire·

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments. "CEL-SCI is very uniquely positioned at this moment